Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

B7188

Sigma-Aldrich

Blonanserin

≥98% (HPLC)

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H30FN3
Número de CAS:
132810-10-7
Peso molecular:
367.50
MDL number:
MFCD00893838
UNSPSC Code:
12352200
PubChem Substance ID:
329773292
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: ≥10 mg/mL

originator

Dainippon Sumitomo

storage temp.

room temp

SMILES string

CCN1CCN(CC1)c2cc(-c3ccc(F)cc3)c4CCCCCCc4n2

InChI

1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3

InChI key

XVGOZDAJGBALKS-UHFFFAOYSA-N

Biochem/physiol Actions

Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.

Features and Benefits

This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H413

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Atsushi Hamuro et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 10(4), 198-200 (2010-12-17)
The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present study was a 12-week, prospective, structured clinical trial of blonanserin for the treatment
Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study.
Koji Kato et al.
Asian journal of psychiatry, 6(2), 182-183 (2013-03-08)
Improvement in quetiapine-induced hypoglycemia following a switch to blonanserin.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(4), 370-371 (2012-05-26)
Taro Kishi et al.
Journal of psychiatric research, 47(2), 149-154 (2012-11-08)
There is uncertainty about the efficacy and tolerability of blonanserin in schizophrenia. PubMed, the Cochrane Library databases, PsycINFO, and Google Scholar were searched up to September 2012. A systematic review and meta-analysis of individual patient data from randomized, controlled trials
Yu-Guan Wen et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 903, 46-52 (2012-07-24)
Blonanserin is a novel atypical antipsychotic with highly selective receptor antagonist activity to dopamine D₂ and 5-HT(2A). N-desethyl blonanserin (blonanserin C) is its major active metabolite in human plasma. Herein we report a new highly sensitive, selective, and rapid liquid
Ver todos los artículos relacionados

Artículos

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico